Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 11 | 2019 | 763 | 1.070 |
Why?
|
| Spinal Stenosis | 1 | 2017 | 26 | 0.600 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2017 | 25 | 0.590 |
Why?
|
| Paclitaxel | 2 | 2014 | 460 | 0.480 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2014 | 276 | 0.480 |
Why?
|
| Glioma | 3 | 2014 | 285 | 0.480 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 94 | 0.470 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 556 | 0.440 |
Why?
|
| Ophthalmoplegia | 1 | 2012 | 11 | 0.430 |
Why?
|
| Orbit | 1 | 2012 | 37 | 0.420 |
Why?
|
| Head Injuries, Penetrating | 1 | 2012 | 54 | 0.400 |
Why?
|
| Wounds, Gunshot | 1 | 2012 | 71 | 0.390 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1169 | 0.360 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2006 | 17 | 0.290 |
Why?
|
| Neurofibromatosis 1 | 1 | 2006 | 36 | 0.290 |
Why?
|
| Drug Implants | 3 | 2002 | 34 | 0.270 |
Why?
|
| Nevus, Blue | 1 | 2003 | 5 | 0.240 |
Why?
|
| Nitric Oxide Donors | 1 | 2002 | 12 | 0.220 |
Why?
|
| Hemangioma, Cavernous | 1 | 2003 | 69 | 0.220 |
Why?
|
| Polyamines | 1 | 2002 | 32 | 0.220 |
Why?
|
| Vasospasm, Intracranial | 1 | 2002 | 36 | 0.220 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 1056 | 0.210 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2002 | 137 | 0.210 |
Why?
|
| Oligodendroglioma | 2 | 2019 | 45 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2017 | 534 | 0.190 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2019 | 4 | 0.180 |
Why?
|
| Rats, Inbred F344 | 2 | 2014 | 156 | 0.170 |
Why?
|
| Endoscopy | 3 | 2016 | 332 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 100 | 0.170 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 178 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2016 | 3362 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 546 | 0.160 |
Why?
|
| Craniotomy | 3 | 2015 | 88 | 0.160 |
Why?
|
| Kisspeptins | 1 | 2017 | 4 | 0.160 |
Why?
|
| Cerebral Angiography | 2 | 2012 | 196 | 0.160 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 37 | 0.160 |
Why?
|
| Cervical Cord | 1 | 2017 | 6 | 0.150 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2017 | 16 | 0.150 |
Why?
|
| Astrocytes | 1 | 2017 | 139 | 0.150 |
Why?
|
| Cauda Equina | 2 | 2007 | 13 | 0.150 |
Why?
|
| Nose Neoplasms | 1 | 2016 | 31 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 2360 | 0.150 |
Why?
|
| Gout | 1 | 2017 | 76 | 0.140 |
Why?
|
| Humans | 27 | 2019 | 86643 | 0.140 |
Why?
|
| Paranasal Sinuses | 1 | 2016 | 60 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 157 | 0.140 |
Why?
|
| Enuresis | 3 | 2000 | 4 | 0.140 |
Why?
|
| Microspheres | 2 | 2014 | 101 | 0.140 |
Why?
|
| Autophagy | 1 | 2017 | 149 | 0.140 |
Why?
|
| Paresis | 1 | 2015 | 15 | 0.140 |
Why?
|
| Rats | 4 | 2014 | 3990 | 0.130 |
Why?
|
| Syndrome | 2 | 2015 | 446 | 0.130 |
Why?
|
| Reflex, Startle | 3 | 2000 | 32 | 0.130 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 36 | 0.130 |
Why?
|
| Male | 14 | 2019 | 40965 | 0.120 |
Why?
|
| Propofol | 1 | 2014 | 89 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 95 | 0.120 |
Why?
|
| Hypertriglyceridemia | 1 | 2014 | 67 | 0.120 |
Why?
|
| Chemokines | 1 | 2013 | 73 | 0.120 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 2426 | 0.120 |
Why?
|
| Motor Cortex | 1 | 2015 | 195 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 391 | 0.110 |
Why?
|
| Aspartic Acid | 1 | 2013 | 64 | 0.110 |
Why?
|
| Seizures | 1 | 2015 | 297 | 0.110 |
Why?
|
| Carotid Artery Injuries | 1 | 2012 | 22 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 426 | 0.110 |
Why?
|
| Maxillary Sinus | 1 | 2012 | 26 | 0.110 |
Why?
|
| Carotid Artery, Internal | 1 | 2012 | 69 | 0.110 |
Why?
|
| Propionibacterium acnes | 1 | 2011 | 6 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 2601 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 2011 | 54 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 164 | 0.100 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2011 | 47 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2014 | 272 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 621 | 0.100 |
Why?
|
| Meningocele | 1 | 2010 | 5 | 0.100 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2010 | 4 | 0.100 |
Why?
|
| Occipital Bone | 1 | 2010 | 18 | 0.100 |
Why?
|
| Carbocyanines | 2 | 2007 | 18 | 0.090 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2000 | 183 | 0.090 |
Why?
|
| Scorpion Venoms | 2 | 2007 | 25 | 0.090 |
Why?
|
| Animals | 9 | 2017 | 26582 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 1686 | 0.090 |
Why?
|
| Choroid Plexus | 1 | 2009 | 14 | 0.090 |
Why?
|
| Back Injuries | 1 | 2009 | 6 | 0.090 |
Why?
|
| Wounds, Stab | 1 | 2009 | 9 | 0.090 |
Why?
|
| Pneumocephalus | 1 | 2009 | 10 | 0.090 |
Why?
|
| Third Ventricle | 1 | 2009 | 11 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 184 | 0.090 |
Why?
|
| Liver | 1 | 2014 | 1230 | 0.090 |
Why?
|
| Adult | 6 | 2019 | 25648 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 383 | 0.090 |
Why?
|
| Cysts | 1 | 2009 | 104 | 0.080 |
Why?
|
| Hydrocephalus | 1 | 2009 | 101 | 0.080 |
Why?
|
| Brain Diseases | 1 | 2009 | 180 | 0.080 |
Why?
|
| Hypertension | 1 | 2017 | 1141 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2007 | 425 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1197 | 0.080 |
Why?
|
| Subdural Effusion | 1 | 2007 | 2 | 0.080 |
Why?
|
| Brain | 3 | 2012 | 2216 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6509 | 0.070 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2006 | 43 | 0.070 |
Why?
|
| Neoplasms | 2 | 2013 | 2898 | 0.070 |
Why?
|
| Female | 10 | 2017 | 44532 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2207 | 0.060 |
Why?
|
| Ferric Compounds | 1 | 2005 | 38 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1464 | 0.060 |
Why?
|
| Neurosurgical Procedures | 3 | 2014 | 213 | 0.060 |
Why?
|
| Nanotechnology | 1 | 2005 | 68 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2903 | 0.060 |
Why?
|
| Intelligence | 2 | 2000 | 71 | 0.060 |
Why?
|
| Cisterna Magna | 1 | 2002 | 10 | 0.060 |
Why?
|
| Polyvinyls | 1 | 2002 | 17 | 0.060 |
Why?
|
| Basilar Artery | 1 | 2002 | 41 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2005 | 363 | 0.060 |
Why?
|
| Carmustine | 1 | 2002 | 70 | 0.050 |
Why?
|
| Bone Marrow Diseases | 1 | 2002 | 40 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 104 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 116 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 270 | 0.050 |
Why?
|
| Middle Aged | 5 | 2017 | 25028 | 0.050 |
Why?
|
| Guanine | 1 | 2002 | 208 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2002 | 1961 | 0.050 |
Why?
|
| Habituation, Psychophysiologic | 2 | 1999 | 11 | 0.050 |
Why?
|
| Rabbits | 1 | 2002 | 636 | 0.050 |
Why?
|
| Reoperation | 2 | 2015 | 597 | 0.050 |
Why?
|
| Recurrence | 2 | 2015 | 1139 | 0.050 |
Why?
|
| Polymers | 1 | 2001 | 202 | 0.050 |
Why?
|
| Neural Inhibition | 1 | 1999 | 97 | 0.040 |
Why?
|
| Survival Rate | 1 | 2002 | 1863 | 0.040 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2017 | 12 | 0.040 |
Why?
|
| Cues | 1 | 1999 | 175 | 0.040 |
Why?
|
| Affective Symptoms | 1 | 1997 | 47 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2017 | 86 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 78 | 0.040 |
Why?
|
| Nasal Obstruction | 1 | 2016 | 21 | 0.040 |
Why?
|
| Arousal | 1 | 1997 | 170 | 0.040 |
Why?
|
| Microglia | 1 | 2017 | 102 | 0.040 |
Why?
|
| Epistaxis | 1 | 2016 | 19 | 0.040 |
Why?
|
| Indazoles | 1 | 2016 | 68 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2016 | 73 | 0.040 |
Why?
|
| Headache | 1 | 2016 | 73 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 458 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2232 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2015 | 32 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 7993 | 0.030 |
Why?
|
| Neuroma, Acoustic | 1 | 2014 | 20 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 293 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 73 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 73 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 2014 | 41 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 300 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 347 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2014 | 58 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 301 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 102 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 370 | 0.030 |
Why?
|
| Language | 1 | 2015 | 151 | 0.030 |
Why?
|
| Aged | 3 | 2017 | 18415 | 0.030 |
Why?
|
| Infant | 2 | 2010 | 3046 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 292 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2014 | 281 | 0.030 |
Why?
|
| Child | 5 | 2007 | 6927 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 3640 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 468 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 916 | 0.030 |
Why?
|
| Oncolytic Virotherapy | 1 | 2012 | 41 | 0.030 |
Why?
|
| Mice | 3 | 2017 | 11352 | 0.030 |
Why?
|
| RNA Stability | 1 | 2012 | 86 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 2438 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2015 | 548 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 311 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 318 | 0.030 |
Why?
|
| Cefazolin | 1 | 2011 | 7 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2010 | 3612 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2011 | 61 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 439 | 0.020 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2010 | 3 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 15 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2010 | 22 | 0.020 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2010 | 25 | 0.020 |
Why?
|
| Tissue Adhesives | 1 | 2010 | 23 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2012 | 342 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2010 | 47 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 113 | 0.020 |
Why?
|
| Septum Pellucidum | 1 | 2009 | 3 | 0.020 |
Why?
|
| Spinal Canal | 1 | 2009 | 4 | 0.020 |
Why?
|
| Lateral Ventricles | 1 | 2009 | 12 | 0.020 |
Why?
|
| Microsurgery | 1 | 2010 | 84 | 0.020 |
Why?
|
| Spinal Diseases | 1 | 2009 | 44 | 0.020 |
Why?
|
| Emphysema | 1 | 2009 | 22 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 418 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1531 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 294 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 930 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 364 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 232 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2012 | 395 | 0.020 |
Why?
|
| Acoustic Stimulation | 2 | 1999 | 130 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1376 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 44 | 0.020 |
Why?
|
| Photons | 1 | 2007 | 46 | 0.020 |
Why?
|
| Klippel-Feil Syndrome | 1 | 2006 | 1 | 0.020 |
Why?
|
| Torticollis | 1 | 2006 | 11 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2261 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1384 | 0.020 |
Why?
|
| Growth | 1 | 2006 | 43 | 0.020 |
Why?
|
| Postural Balance | 1 | 2006 | 42 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1981 | 0.020 |
Why?
|
| Scoliosis | 1 | 2006 | 31 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 3679 | 0.020 |
Why?
|
| Body Height | 1 | 2006 | 99 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 21 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 746 | 0.020 |
Why?
|
| Comorbidity | 2 | 2000 | 943 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 242 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 579 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 59 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 134 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1313 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 353 | 0.020 |
Why?
|
| Dogs | 1 | 2006 | 685 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2005 | 178 | 0.020 |
Why?
|
| Nanostructures | 1 | 2005 | 77 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 268 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2006 | 193 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 5417 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 3241 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2005 | 429 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 50 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2002 | 21 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2002 | 25 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 275 | 0.010 |
Why?
|
| Necrosis | 1 | 2002 | 204 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 303 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2015 | 8489 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2002 | 117 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 1047 | 0.010 |
Why?
|
| Pleasure-Pain Principle | 1 | 1997 | 2 | 0.010 |
Why?
|
| Child Development | 1 | 1999 | 163 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1999 | 912 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 920 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 8981 | 0.010 |
Why?
|
| Heart Rate | 1 | 1997 | 492 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1805 | 0.010 |
Why?
|
| Attention | 1 | 1997 | 388 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 2271 | 0.010 |
Why?
|